4.5 Article

Interference with work in fibromyalgia - effect of treatment with pregabalin and relation to pain response

期刊

BMC MUSCULOSKELETAL DISORDERS
卷 12, 期 -, 页码 -

出版社

BIOMED CENTRAL LTD
DOI: 10.1186/1471-2474-12-125

关键词

-

资金

  1. Faculty of Medicine, Georg-August-University Gottingen
  2. Oxford Pain Relief Trust
  3. Nuffield Division of Anaesthetics, University of Oxford
  4. Pfizer Inc.
  5. NIHR Biomedical Research Centre
  6. Bandolier
  7. Reckitt Benckiser
  8. Georg-August-University Gottingen
  9. University Children's Hospital Zurich
  10. Oxford Medical Knowledge
  11. Merck
  12. Pfizer
  13. Menarini
  14. Lundbeck
  15. AstraZeneca
  16. Abbott
  17. GSK
  18. Aspreva
  19. Janssen-Cilag
  20. Gilead
  21. Napp
  22. UK government
  23. Esteve
  24. Grunenthal
  25. IMS
  26. Archimedes

向作者/读者索取更多资源

Background: Clinical trials in chronic pain often collect information about interference with work as answers to component questions of commonly used questionnaires but these data are not normally analysed separately. Methods: We performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks. We analysed data on interference with work, inferred from answers to component questions of Fibromyalgia Impact Questionnaire (FIQ), Short Form 36 Health Survey, Sheehan Disability Scale, and Multidimensional Assessment of Fatigue, including How many days in the past week did you miss work, including housework, because of fibromyalgia? from FIQ. Analyses were performed according to randomised treatment group (pregabalin 150-600 mg daily or placebo), pain improvement (0-10 numerical pain rating scale scores at trial beginning vs. end), and end of trial pain state (100 mm visual analogue pain scale [VAS]). Results: Comparing treatment group average outcomes revealed modest improvement over the duration of the trials, more so with active treatment than with placebo. For the 'work missed' question from FIQ the change for patients on placebo was from 2.2 (standard deviation [SD] 2.3) days of work lost per week at trial beginning to 1.9 (SD 2.1) days lost at trial end (p < 0.01). For patients on 600 mg pregabalin the change was from 2.1 (SD 2.2) days to 1.6 (SD 2.0) days (p < 0.001). However, the change in days of work lost was substantial in patients with a good pain response: from 2.0 (SD 2.2) days to 0.97 (SD 1.6) days (p < 0.0001) for those experiencing >/= 50% pain improvement and from 1.9 (SD 2.2) days to 0.73 (SD 1.4) days (p < 0.0001) for those achieving a low level of pain at trial end (< 30 mm on the VAS). Patients achieving both >/= 50% pain improvement and a pain score < 30 mm on the VAS had the largest improvement, from 2.0 (SD 2.2) days to 0.60 (SD 1.3) days (p < 0.0001). Analysing answers to the other questions yielded qualitatively similar results. Conclusions: Effective pain treatment goes along with benefit regarding work. A reduction in time off work > 1 day per week can be achieved in patients with good pain responses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据